StemGen Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Simon Dawson

Chief executive officer

US$18.5k

Total compensation

CEO salary percentage100.0%
CEO tenure3.8yrs
CEO ownership11.3%
Management average tenure1.8yrs
Board average tenureno data

Recent management updates

Recent updates

CEO Compensation Analysis

How has Simon Dawson's remuneration changed compared to StemGen's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2022n/an/a

-US$537k

Dec 31 2021n/an/a

-US$449k

Sep 30 2021n/an/a

-US$482k

Jun 30 2021US$19kUS$19k

-US$433k

Mar 31 2021n/an/a

-US$362k

Dec 31 2020n/an/a

-US$316k

Sep 30 2020n/an/a

-US$263k

Jun 30 2020US$6kUS$6k

-US$231k

Mar 31 2020n/an/a

-US$288k

Dec 31 2019n/an/a

-US$431k

Sep 30 2019n/an/a

-US$430k

Jun 30 2019US$40kUS$10k

-US$426k

Compensation vs Market: Simon's total compensation ($USD18.50K) is below average for companies of similar size in the US market ($USD740.57K).

Compensation vs Earnings: Simon's compensation has increased whilst the company is unprofitable.


CEO

Simon Dawson (40 yo)

3.8yrs

Tenure

US$18,500

Compensation

Mr. Simon Dawson has been President, Secretary, Treasurer, Chief Executive Officer and Director at StemGen Inc. since January 29, 2019 and is its Chairman of the Board. He was Principal Financial Officer a...


Leadership Team

NamePositionTenureCompensationOwnership
Simon Dawson
Chairman3.8yrsUS$18.50k11.31%
$ 516.7k
Ron McNair
Chief Financial Officer1.8yrsno datano data
Barbara Burns
Chief Communications Officer & Group PR1.8yrsno datano data
Erik Stroman
Executive VP of Sales1.8yrsno datano data
Sean Tabatabai
Chief Strategy Officer1.8yrsno datano data
Ian Dawson
Senior Vice President of Partner Relationsno datano data11.31%
$ 516.7k

1.8yrs

Average Tenure

Experienced Management: SGNI's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/11/23 23:17
End of Day Share Price 2022/08/26 00:00
Earnings2022/03/31
Annual Earnings2021/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

StemGen, Inc. is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.